筋骨格系関連の各種提携契約：契約条件・合意内容

当レポートでは、筋骨格系関連の各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約区分・開発ステージ・技術区分・適応症区分別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 筋骨格系関連の契約動向

• イントロダクション
• 長期契約
• 大手製薬企業における筋骨格系の契約活動
• 筋骨格系の提携に消極的な大手製薬企業
• 契約タイプ別
• 産業分野別
• 開発段階別
• 技術タイプ別
• 症状別
• 平均契約期間

第3章 主要契約

• イントロダクション
• 主要契約：契約額別
• 大手製薬関連の主要契約

第4章 大手製薬企業による筋骨格系関連の各種契約

• イントロダクション
• 大手企業による提携取引の利用方法
• 企業プロファイル

第5章 筋骨格系の提携契約ディレクトリ

• イントロダクション
• 契約タイプ別
• 開発段階別
• 技術タイプ別

第6章　筋骨格系の契約：症状別

• イントロダクション
• 契約：治療指標別
  • 筋骨格系
  • 関節炎
  • 変形性関節症
  • 乾癬性関節炎
  • 関節リウマチ
  • 骨折
  • 腰
  • 痛風
  • 膝
  • 背痛
  • 骨痛
  • 筋肉痛
  • 剛性
  • 骨粗しょう症
  • パジェット病
  • 脊髄性筋萎縮症

第7章　提携リソースセンター

• オンライン提携
• 提携イベント
• 参考資料

付録

Wildwood Venturesについて

図表

Global Musculoskeletal Partnering 2012-2018: Deal trends, players and financials provides comprehensive understanding and unprecedented access to the musculoskeletal partnering deals and agreements entered into by the worlds leading healthcare companies

Description

Global Musculoskeletal Partnering 2012 to 2018 provides the full collection of Musculoskeletal disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Trends in Musculoskeletal partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Musculoskeletal partnering agreement structure

Musculoskeletal partnering contract documents

Top Musculoskeletal deals by value

Most active Musculoskeletal dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Musculoskeletal deals.

The report presents financial deal terms values for Musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Musculoskeletal dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Musculoskeletal dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Musculoskeletal deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Musculoskeletal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Musculoskeletal deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Musculoskeletal partnering deals by specific Musculoskeletal target announced since 2012. The chapter is organized by specific Musculoskeletal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Musculoskeletal partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Musculoskeletal partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Musculoskeletal technologies and products.

Report scope

Global Musculoskeletal Partnering 2012 to 2018 is intended to provide the reader with an in-depth understanding and access to Musculoskeletal trends and structure of deals entered into by leading companies worldwide.

Global Musculoskeletal Partnering 2012 to 2018 includes:

• Trends in Musculoskeletal dealmaking in the biopharma industry since 2012
• Analysis of Musculoskeletal deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Musculoskeletal deal contract documents
• Comprehensive access to over 3500 Musculoskeletal deal records
• The leading Musculoskeletal deals by value since 2012
• Most active Musculoskeletal dealmakers since 2012
• The report includes deals for the following indications: Arthritis, Ankylosing spondylitis, Juvenile arthritis, Osteoarthritis, Psoriatic arthriti, Rheumatoid arthritis, Bone fracture, Hip, Carpel tunnel syndrome, Frozen shoulder, Gout, Knee, Meniscus damage, Muscular dystrophy, Osteoporosis, Paget's disease, Spinal muscular atrophy, Bone pain, Back pain, Muscular pain, Stiffness, Weakness, plus other musculoskeletal indications.

In Global Musculoskeletal Partnering 2012 to 2018, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Musculoskeletal Partnering 2012-2018 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are the sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Musculoskeletal Partnering 2012 to 2018 provides the reader with the following key benefits:

• In-depth understanding of Musculoskeletal deal trends since 2012
• Access Musculoskeletal deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between Musculoskeletal partner companies
• Comprehensive access to over 750 links to actual Musculoskeletal deals entered into by the world's biopharma companies
• Indepth review of Musculoskeletal deals entered into by the top 25 most active dealmakers
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner Musculoskeletal opportunities
• Uncover companies actively partnering Musculoskeletal opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Musculoskeletal dealmaking

• 2.1. Introduction
• 2.2. Musculoskeletal partnering over the years
• 2.3. Musculoskeletal partnering by deal type
• 2.4. Musculoskeletal partnering by industry sector
• 2.5. Musculoskeletal partnering by stage of development
• 2.6. Musculoskeletal partnering by technology type
• 2.7. Musculoskeletal partnering by therapeutic indication

Chapter 3 -Financial deal terms for Musculoskeletal partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for Musculoskeletal partnering
• 3.3. Musculoskeletal partnering headline values
• 3.4. Musculoskeletal deal upfront payments
• 3.5. Musculoskeletal deal milestone payments
• 3.6. Musculoskeletal royalty rates

Chapter 4 - Leading Musculoskeletal deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in Musculoskeletal partnering
• 4.3. List of most active dealmakers in Musculoskeletal
• 4.4. Top Musculoskeletal deals by value

Chapter 5 - Musculoskeletal contract document directory

• 5.1. Introduction
• 5.2. Musculoskeletal partnering deals where contract document available

Chapter 6 - Musculoskeletal dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by Musculoskeletal therapeutic target

Appendices

• Appendix 1 - Directory of Musculoskeletal deals by company A-Z 2012 to 2018
• Appendix 2 - Directory of Musculoskeletal deals by deal type 2012 to 2018
• Appendix 3 - Directory of Musculoskeletal deals by stage of development 2012 to 2018
• Appendix 4 - Directory of Musculoskeletal deals by technology type 2012 to 2018
• Further reading on dealmaking
• Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from CurrentPartnering
• Table of figures
• Figure 1: Musculoskeletal partnering since 2012
• Figure 2: Musculoskeletal partnering by deal type since 2012
• Figure 3: Musculoskeletal partnering by industry sector since 2012
• Figure 4: Musculoskeletal partnering by stage of development since 2012
• Figure 5: Musculoskeletal partnering by technology type since 2012
• Figure 6: Musculoskeletal partnering by indication since 2012
• Figure 7: Musculoskeletal deals with a headline value
• Figure 8: Musculoskeletal deals with upfront payment values
• Figure 9: Musculoskeletal deals with milestone payment
• Figure 10: Musculoskeletal deals with royalty rates
• Figure 11: Active Musculoskeletal dealmaking activity- 2012 to 2018
• Figure 12: Top Musculoskeletal deals by value since 2012